hackint0sh/New-Dataset huggingface dataset:
1) Determine the mortality associated with CKD, and the risk factors driving its development and progression in Malawian adults 2) Investigate the impacts of different models for integrating screening and prevention strategies for CKD and its risk factors into health services for other long-term conditions in low- and middle-income countries 3) With patients, carers, healthcare workers and policy makers, evaluate the feasibility and acceptability of different potential models for integrating CKD screening and prevention strategies into health services for high-risk patient groups in Malawi conditions: Chronic Kidney Diseases conditions: Non-Communicable Chronic Diseases conditions: Non-communicable Disease conditions: Kidney Diseases studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: OTHER count: 1100 type: ESTIMATED name: No intervention; observational study measure: Aim 1, objective 3 primary outcome measure measure: Aim 1, objective 2 primary outome measure measure: Aim 1, objective 1 primary outcome measure: measure: Aim 1, objective 3 secondary outcome measure 1: measure: Aim 1, objective 3 secondary outcome measure 2: measure: Aim 1, objective 3 secondary outcome measure 3: measure: Aim 1, objective 3 secondary outcome measure 4: measure: Aim 1, objective 3 secondary outcome measure 5: measure: Aim 1, objective 3 secondary outcome measure 6: measure: Aim 1, objective 2 secondary outcome measure: measure: Aim 1, objective 1 secondary outcome measure: sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Malawi Epidemiology and Intervention Research Unit status: RECRUITING city: Chilumba state: Karonga zip: P.O. Box 46 country: Malawi name: Laurence Tembo role: CONTACT phone: +265 888 348 705 email: charlotte.snead@lstmed.ac.uk name: Mia Crampin, MB ChB msC role: CONTACT email: mia.crampin@lshtm.ac.uk name: Charlotte Snead, BA BMBCh role: PRINCIPAL_INVESTIGATOR name: Henry Mwandumba role: SUB_INVESTIGATOR name: Alison Price, BVSc DPhil role: SUB_INVESTIGATOR name: Felix Limbani, PhD MPH BSc role: SUB_INVESTIGATOR name: Dominic Taylor, MD MBChB role: SUB_INVESTIGATOR name: Chimota Phiri role: SUB_INVESTIGATOR name: Charles Munthali role: SUB_INVESTIGATOR name: Mia Crampin, MBChB MSc role: SUB_INVESTIGATOR lat: -11.1 lon: 33.68333 hasResults: False
nctId: NCT06312059 id: KNC-GMS-002 briefTitle: Goat or Cow Milk Based Infant Formula GMS overallStatus: RECRUITING date: 2023-12-14 date: 2024-08-15 date: 2024-08-15 date: 2024-03-15 date: 2024-03-15 name: Kendal Nutricare Ltd class: INDUSTRY name: ObvioHealth briefSummary: This study is a non-inferiority, decentralized, randomized, double-blind, controlled clinical trial evaluating the growth, tolerance, and safety of a goat's-milk test infant formula (Test Formula 1; TF1) and a cow's-milk test infant formula (Test Formula 2; TF2), each compared to a cow's-milk infant formula commercially available in the United States (Control Formula; CF). conditions: Growth studyType: INTERVENTIONAL phases: PHASE2 phases: PHASE3 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: OTHER masking: QUADRUPLE maskingDescription: RP Over stickered TP in blank packaging. whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 264 type: ESTIMATED name: "Similac® Advance Infant Formula Powder name: "Kendamil Cow milk test product name: "Kendamil goat milk test product measure: Growth as compared against WHO growth charts measure: Safety measure: Tolerability- Monitoring of stool consistency measure: Tolerability - fussiness measure: Mean Daily Recumbent Length Gain measure: Mean Daily Head Circumference Gain sex: ALL maximumAge: 14 Days stdAges: CHILD facility: ObvioHealth USA, Inc. status: RECRUITING city: New York state: New York zip: 10001 country: United States name: Parth Shah role: CONTACT phone: 513-571-5377 email: parth.shah@obviohealth.com lat: 40.71427 lon: -74.00597 hasResults: False
nctId: NCT06312046 id: 2018 374-31 briefTitle: Motor-cognitive Performance in People With Multiple Sclerosis acronym: HiBalance-MS overallStatus: RECRUITING date: 2024-02-26 date: 2025-12-31 date: 2027-08-31 date: 2024-03-15 date: 2024-03-15 name: Karolinska Institutet class: OTHER name: Karolinska University Hospital briefSummary: Having a neurological disease such as multiple sclerosis (MS) leads to difficulties in balance and gait with or without concurrent performance of cognitive tasks, hindering activity performance and influencing the possibilities for an independent lifestyle.
nctId: NCT06312033 id: MRTG_P01 briefTitle: Estradiol's Effect on Brain Volume and Connectivity overallStatus: COMPLETED date: 2018-08-01 date: 2019-07-31 date: 2021-12-31 date: 2024-03-15 date: 2024-03-15 name: International Research Training Group 2804 class: OTHER name: University Hospital Tübingen name: German Research Foundation name: Werner Reichardt Centrum für Integrative Neurowissenschaften (CIN) briefSummary: Ovarian hormones are not only modulators of cognitive function, emotion regulation and mental health, but also seem to affect brain plasticity and functional connectivity, During the menstrual cycle, women experience cyclic fluctuation of the ovarian hormone estradiol, which is closely associated with neuroplasticity/changes in brain structure in regions with high estradiol receptor density, such as the amygdala, hippocampus/parahippocampus, anterior cingulate cortex (ACC), striatum, and prefrontal cortex (PFC). Further functional connectivity between these areas seems to be associated with hormonal changes dependent on the menstrual cycle phase. But next to estradiol, also other hormones like progesterone fluctuate across the menstrual cycle. In the past, effects of ovarian hormone levels were often investigated in combination. However, one way to disentangle the impact of estradiol from that of other hormones on neuroplasticity, emotion regulation and mood states, can be the experimental increase of estradiol via estradiol administration. In this double-blinded within-subject study, women were administered either estradiol valerate or placebo during the early follicular phase (thus when ovarian hormone concentrations are low) before undergoing neuroimaging.
Parts of the study are already described in Rehbein et al., 2021 and 2022. conditions: Emotion Regulation conditions: Estradiol studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: CROSSOVER interventionModelDescription: The intervention assessed the effect of estradiol administration on stress reactivity using a double blind randomized within -between placebo-controled design with repeated measures. primaryPurpose: OTHER masking: TRIPLE maskingDescription: Neither participant or investigator knew the timepoint of drug or placebo administration. Pills were prepared by independent members of the university hospital. whoMasked: PARTICIPANT whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 32 type: ACTUAL name: Estradiol Valerate name: Placebo measure: Impact of E2 concentration on brain structure measure: Impact of E2 concentration and state emotion regulation on brain structure measure: Impact of E2 concentration and emotion regulation traits on brain structure measure: Impact of E2 concentration on resting state functional connectivity measure: Impact of E2 concentration and state emotion regulation on connectivity measure: Impact of E2 concentration and emotion regulation traits on functional connectivity measure: Impact of E2 concentration and associated structural brain changes on connectivity measure: Impact of E2 concentration and self-esteem on brain structure measure: Impact of E2 concentration and self-esteem on functional connectivity measure: Impact of E2 concentration and subjective mood on brain structure measure: Impact of E2 concentration and state anxiety on brain structure measure: Impact of E2 concentration and subjective mood on functional connectivity measure: Impact of E2 concentration and state anxiety on functional connectivity measure: Impact of E2 administration on E2 concentrations measure: Impact of E2 administration on E2-progesterone ratio measure: Impact of E2 administration on testosterone and progesterone concentration sex: FEMALE minimumAge: 19 Years maximumAge: 35 Years stdAges: ADULT facility: University of Tuebingen; Department of Psychiatry & Psychotherapy city: Tuebingen state: BW zip: 72076 country: Germany lat: 48.52266 lon: 9.05222 hasResults: False
nctId: NCT06312020 id: HZNP-HZN-1116-201 briefTitle: A Phase 2 Study to Investigate Efficacy and Safety of HZN-1116 in Participants With Sjogren's Syndrome overallStatus: NOT_YET_RECRUITING date: 2024-03-15 date: 2026-09-03 date: 2026-11-26 date: 2024-03-15 date: 2024-03-15 name: Horizon Therapeutics Ireland DAC class: INDUSTRY briefSummary: The purpose of this study is to measure the efficacy and safety of HZN-1116 in participants with Sjogren's syndrome (SS). conditions: Sjogren's Syndrome studyType: INTERVENTIONAL phases: PHASE2 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 262 type: ESTIMATED name: HZN-1116 name: Placebo measure: Change from baseline in European Alliance of Associations for Rheumatology (EULAR) Sjogren's Syndrome Disease Activity Index (ESSDAI) (Population #1) measure: Change from baseline in EULAR Sjogren's Syndrome Patient Reported Index (ESSPRI) (Population #2) measure: Change from baseline in ESSDAI (Population #1) measure: Proportion of Participants achieving ESSDAI [5] response (Population #1) measure: Change from baseline in ESSPRI pain domain score (Population #1) measure: Change from baseline in Diary for Assessing Sjogren's Patient-Reported Outcome Index (DASPRI) pain domain score (Population #1) measure: Change from baseline in ESSPRI fatigue domain score (Population #1) measure: Change from baseline in DASPRI fatigue domain score (Population #1) measure: Change from baseline in ESSPRI dryness domain score (Population #1) measure: Change from baseline in DASSPRI dryness domain score (Population #1) measure: Change from baseline in tender joint count (TJC) (Population #1) measure: Change from baseline in swollen joint count (SJC) (Population #1) measure: Change from baseline in 36-item Short Form Survey (SF-36) physical component score (PCS) (Population #1) measure: Change from baseline in 36-item Short Form Survey (SF-36) mental component score (MCS) (Population #1) measure: Change from baseline in patient-reported outcomes measurement information system (PROMIS)-Fatigue SF-10a (Population #1) measure: Change from baseline in DASPRI (Population #2) measure: Proportion of Participants achieving ESSPRI [1.5] response (Population #2) measure: Change from baseline in ESSPRI pain domain (Population #2) measure: Change from baseline in ESSPRI fatigue domain (Population #2) measure: Change from baseline in ESSPRI dryness domain (Population #2) measure: Change from baseline in SF-36 PCS Score (Population #2) measure: Change from baseline in 36-item Short Form Survey (SF-36) mental component score MCS (Population #2) measure: Change from baseline in PROMIS-Fatigue SF-10a (Population #2) measure: Serum concentration of HZN-1116 starting at Week 1 through study completion (Population #1 and #2) measure: Proportion of Participants who develop anti drug antibodies (ADA) over time (Population #1 and #2) sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06312007 id: UH23030202 briefTitle: Semi-seated Holding Position to Reduce Stress Responses in in the Neonatal Intensive Care Unit overallStatus: COMPLETED date: 2023-07-01 date: 2023-11-01 date: 2023-12-01 date: 2024-03-15 date: 2024-03-15 name: Hasanuddin University class: OTHER briefSummary: This study to compare half semi seated position and side lying position with cortisol level on the neonate's stress respon conditions: Semi Seated Position conditions: Side Lying Position studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Intervention semi seated position Control side lying position primaryPurpose: OTHER masking: NONE count: 45 type: ACTUAL name: Semi seated position name: side lying position measure: Kortisol level measure: Oxytocin level sex: ALL minimumAge: 32 Weeks maximumAge: 42 Weeks stdAges: CHILD facility: Hasanuddin University city: Makassar state: South Sulawesi country: Indonesia lat: -5.14861 lon: 119.43194 hasResults: False
nctId: NCT06311981 id: SPHIC-TR-THLC2023-08 briefTitle: Carbon Ion Radiotherapy for Locally Advanced Lung Cancer in Elderly Patients overallStatus: RECRUITING date: 2024-04-01 date: 2025-06-17 date: 2026-06-17 date: 2024-03-15 date: 2024-03-15 name: Jian Chen class: OTHER briefSummary: To observe the effect and toxicity of carbon ion radiotherapy on local advanced non-small cell lung cancer over 75 years old patients. Systemic therapy could be targeted therapy, chemotherapy or immunotherapy. conditions: Non-small Cell Lung Cancer conditions: Older People conditions: Carbon Ion Radiotherapy conditions: Radiotherapy Side Effect studyType: INTERVENTIONAL phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 29 type: ESTIMATED name: carbon ion radiotherapy name: targeted therapy name: single regimen chemotherapy in sequence with radiotherapy measure: Disease progression-free survival rate measure: Incidence of Treatment-induced Adverse Events measure: Local control rate measure: Cause-specific survival rate measure: Overall survival rate sex: ALL minimumAge: 75 Years stdAges: OLDER_ADULT facility: Shanghai Proton and Heavy Ion Center status: RECRUITING city: Shanghai state: Shanghai zip: 201513 country: China name: Jing Li role: CONTACT phone: 86-21-38296678 email: jing.li@sphic.org.cn name: Kun Liu role: CONTACT phone: 86-21-38296678 email: kun.liu@sphic.org.cn name: Jian Chen, MD role: PRINCIPAL_INVESTIGATOR name: Jingfang Mao, PHD role: PRINCIPAL_INVESTIGATOR name: Kai-liang Wu, PHD role: PRINCIPAL_INVESTIGATOR lat: 31.22222 lon: 121.45806 hasResults: False
nctId: NCT06311968 id: SPHIC-TR-THLC2023-07 briefTitle: The Clinical Study of Post-operative Proton Radiotherapy for Thymus Tumor overallStatus: RECRUITING date: 2024-04-01 date: 2027-02-28 date: 2027-02-28 date: 2024-03-15 date: 2024-03-15 name: Jian Chen class: OTHER briefSummary: To observe the efficacy and toxicities of post-operative (R0/R1) proton radiotherapy for locally advanced primary thymus epithelial malignancies. The primary endpoint was progression-free survival and toxicities, and the secondary endpoint was overall survival and cause-specific survival. conditions: Thymus Epithelial Tumor conditions: Proton Radiotherapy conditions: Radiation Toxicity studyType: INTERVENTIONAL phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 55 type: ESTIMATED name: Proton radiotherapy name: combined platinum based chemotherapy measure: Disease progression-free survival rate measure: Incidence of Treatment-induced Adverse Events measure: Overall survival rate measure: Cause-specific survival rate sex: ALL minimumAge: 18 Years maximumAge: 70 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Shanghai Proton and Heavy Ion Center status: RECRUITING city: Shanghai state: Shanghai zip: 201513 country: China name: Jing Li role: CONTACT phone: 86-21-38296678 email: jing.li@sphic.org.cn name: Kun Liu role: CONTACT phone: 86-21-38296678 email: kun.liu@sphic.org.cn name: Jian Chen, MD role: PRINCIPAL_INVESTIGATOR name: Jingfang Mao, PHD role: PRINCIPAL_INVESTIGATOR name: Kai-liang Wu, PHD role: PRINCIPAL_INVESTIGATOR lat: 31.22222 lon: 121.45806 hasResults: False
nctId: NCT06311955 id: SPHIC-TR-THLC2023-06 briefTitle: Clinical Study of Postoperative Carbon Ion Radiotherapy for Thymus Tumor With Residual Tumor overallStatus: RECRUITING date: 2024-04-01 date: 2028-02-28 date: 2029-02-28 date: 2024-03-15 date: 2024-03-15 name: Jian Chen class: OTHER briefSummary: To observe the efficacy and toxicities of heavy ion radiation therapy for locally advanced or advanced primary thymic epithelial malignant tumor received R2 resection. The primary endpoint was progression-free survival and toxicities, and the secondary endpoint was local relapse-free survival, overall survival and cause-specific survival. conditions: Thymic Epithelial Tumor conditions: Radiotherapy Side Effect conditions: Carbon Ion Radiotheray conditions: Heavy Ion Radiotherapy studyType: INTERVENTIONAL phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 48 type: ESTIMATED name: Carbon ion radiotherapy name: combined with platinum-based regimen measure: Disease progression-free survival rate measure: Incidence of Treatment-induced Adverse Events measure: Local-progression free survival rate measure: Overall survival rate measure: Cause-specific survival rate sex: ALL minimumAge: 18 Years maximumAge: 70 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Shanghai Proton and Heavy Ion Center status: RECRUITING city: Shanghai state: Shanghai zip: 201513 country: China name: Jing Li role: CONTACT phone: 86-21-38296678 email: jing.li@sphic.org.cn name: Kun Liu role: CONTACT phone: 86-21-38296678 email: kun.liu@sphic.org.cn name: Jian Chen, MD role: PRINCIPAL_INVESTIGATOR name: Jingfang Mao, PHD role: PRINCIPAL_INVESTIGATOR name: Kai-liang Wu, PHD role: PRINCIPAL_INVESTIGATOR lat: 31.22222 lon: 121.45806 hasResults: False
nctId: NCT06311942 id: Precision AT-02 briefTitle: Triple vs. Dual Adjuvant Therapy Following Liver Resection for HCC. overallStatus: NOT_YET_RECRUITING date: 2024-04-01 date: 2027-12-31 date: 2028-12-31 date: 2024-03-15 date: 2024-03-15 name: Chen Xiaoping class: OTHER briefSummary: Vessels that encapsulate tumor clusters (VETC) is an invasive metastatic factor in HCC independent of the epithelial mesenchyme transition (EMT), and VETC-positive patients have a higher rate of postoperative recurrence. What can be done to improve the surgical prognosis of this group of patients needs to be continuously explored. conditions: HCC studyType: INTERVENTIONAL phases: PHASE4 allocation: NON_RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 300 type: ESTIMATED name: HAIC plus PD-1 inhibitors plus lenvatinib name: PD-1 inhibitors plus lenvatinib measure: DFS measure: OS sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06311929 id: Precision AT-01 briefTitle: Precision Adjuvant Therapy After Surgery for Hepatocellular Carcinoma overallStatus: NOT_YET_RECRUITING date: 2024-04-01 date: 2027-12-31 date: 2028-12-31 date: 2024-03-15 date: 2024-03-15 name: Chen Xiaoping class: OTHER briefSummary: Vessels that encapsulate tumor clusters (VETC) is an invasive metastatic factor in HCC independent of the epithelial mesenchyme transition (EMT), and VETC-positive patients have a higher rate of postoperative recurrence. How to improve the prognosis of this group of patients is an urgent issue to be addressed. conditions: HCC studyType: INTERVENTIONAL phases: PHASE4 allocation: NON_RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 300 type: ESTIMATED name: PD-1 monoclonal antibody and lenvatinib name: PD-1 monoclonal antibody measure: Disease-free survival measure: Overall survival sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06311916 id: Neoadj-Net briefTitle: Efficacy and Safety of Neoadjuvant Therapy in Patients With Resectable HCC Screened by a Multimodal Deep Learning Model. overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2027-12-31 date: 2028-12-31 date: 2024-03-15 date: 2024-03-15 name: Chen Xiaoping class: OTHER briefSummary: Primary liver cancer is one of the most common malignant tumors in the world, and more than 90% of primary liver cancers are pathologically characterized as hepatocellular carcinoma (HCC). The intermediate stage (BCLC-B) HCC is highly heterogeneous, and there is no consensus on the treatment of this stage of the tumor in Western and Eastern countries. New tools are urgently needed to guide the choice of treatment options for patients with this stage of the tumor in order to reduce the risk of postoperative recurrence and the overall survival rate. conditions: HCC studyType: INTERVENTIONAL phases: PHASE4 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 312 type: ESTIMATED name: HAIC + Tirelizumab +lenvatinib +liver resection name: liver resection measure: Disease-free survival measure: Safety Assessment sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06311903 id: 36264PR430/11/23 briefTitle: Norepinephrine in Preperiod of Hypotensive Resuscitation in Hemorrhagic Shock overallStatus: RECRUITING date: 2023-12-01 date: 2024-04-01 date: 2024-04-01 date: 2024-03-15 date: 2024-03-15 name: Tanta University class: OTHER briefSummary: The aim of this work was to investigate the effects of low dose of norepinephrine in preperiod of hypotensive resuscitation in hemorrhagic shock. conditions: Norepinephrine conditions: Hemorrhagic Shock conditions: Hypotensive Resuscitation studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: PREVENTION masking: NONE count: 200 type: ESTIMATED name: Low dose of Norepinephrine (NE) name: High dose of Norepinephrine (NE) measure: 24 hours mortality measure: 28 day mortality measure: Incidence of acute kidney injury measure: Length of hospital stay measure: Length of intensive care unit stay sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Tanta University status: RECRUITING city: Tanta state: El-Gharbia zip: 31527 country: Egypt name: Rabab M Mohamed, MD role: CONTACT phone: 00201069122935 email: rabmoh_30@outlook.com name: Atia G Anwar, MD role: PRINCIPAL_INVESTIGATOR name: Ahmed A Eid, MD role: PRINCIPAL_INVESTIGATOR lat: 30.78847 lon: 31.00192 hasResults: False
nctId: NCT06311890 id: 2023XLA141-2 briefTitle: Study to Evaluate the Efficacy, Safety and Tolerability of Photodynamic Therapy(PDT) With Chlorin-e6 in Treating Moderate to Severe Acne overallStatus: RECRUITING date: 2024-02-01 date: 2026-09-30 date: 2026-09-30 date: 2024-03-15 date: 2024-03-15 name: Xiyuan Hospital of China Academy of Chinese Medical Sciences class: OTHER briefSummary: This study aims to evaluate the clinical efficacy, safety and tolerability of a photodynamic therapy(PDT) based on a new photosensitizer, Chlorin-e6, in the treatment of moderate to severe acne. The hypothesis is that the therapy has good efficacy, safety and tolerability. conditions: Acne conditions: Photodynamic Therapy studyType: INTERVENTIONAL phases: PHASE2 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 46 type: ESTIMATED name: N-chlorin e6 triglumine name: acne removal surgery measure: Change in Global Acne Grading System (GAGS) Relative to Baseline measure: Change in Inflammatory&non-inflammatory Lesion Counts Relative to Baseline measure: Change in Acne-specific Quality of Life Assessment Instrument（Qol-Acne）Relative to Baseline measure: Change in Numerical Rating Scale(NRS) Relative to Baseline measure: Number of participants with abnormalities of Hematological Parameters and Urine Parameters Relative to Baseline measure: Change in Adverse Reaction Management Form(AR-MF) Relative to Baseline sex: ALL minimumAge: 18 Years maximumAge: 50 Years stdAges: ADULT facility: Xiyuan Hospital of China Academy of Chinese Medical Sciences Organization status: RECRUITING city: Beijing zip: 100091 country: China name: Huiyan Chi, doctor role: CONTACT phone: 13811626953 email: chihuiyan@163.com name: Yisheng Zhang, doctor role: CONTACT phone: 15652386117 email: llleera@126.com lat: 39.9075 lon: 116.39723 hasResults: False